Greenhill Gains as Firm Plays Adviser to Actavis

Greenhill & Co. (GHL) gained the most in more than two years after the firm acted as sole adviser to Actavis Plc (ACT) in its $25 billion bid for Forest Laboratories Inc. (FRX)

Greenhill, founded by former Morgan Stanley President Robert F. Greenhill, rose 8.7 percent to $52.98 at 4:15 p.m. in New York. The rally buoyed the stock after a 16 percent slide this year through last week, following a fourth quarter that included a 25 percent drop in advisory revenue.

“There was definitely a great deal of relief to see them on a large deal,” said Brennan Hawken, an analyst at UBS AG, who assigns a neutral rating to the stock. “Often when you have a deal that big, there is more than one adviser. They are getting all the revenue on the buy side.”

Hawken said the stock had become a target of short-sellers, who are probably buying today to cut their losses after betting on a further decline. Jeffrey Taufield, Greenhill’s spokesman, said in an e-mail that the company had no comment.

Actavis, the world’s second-largest generic-drug maker by market value, is seeking to become a developer of brand-name drugs.

To contact the reporter on this story: Sarah Jacob in New York at

To contact the editor responsible for this story: Rick Green at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.